Drug discovery and development focusing on existing medicines: Drug re-profiling strategy

Tohru Mizushima

研究成果: Article

22 引用 (Scopus)

抄録

As a new strategy for drug discovery and development, I focus on drug re-profiling as a way to identify new treatments for diseases. In this strategy, the actions of existing medicines, whose safety and pharmacokinetic effects in humans have already been confirmed clinically and approved for use, are examined comprehensively at the molecular level and the results used for the development of new medicines. This strategy is based on the fact that we still do not understand the underlying mechanisms of action of many existing medicines, and as such the cellular responses that give rise to their main effects and side effects are yet to be elucidated. To this extent, identification of the mechanisms underlying the side effects of medicines offers a means for us to develop safer drugs. The results can also be used for developing existing drugs for use as medicines for the treatment of other diseases. Promoting this research strategy could provide breakthroughs in drug discovery and development. The Authors 2011. Published by Oxford University Press on behalf of the Japanese Biochemical Society. All rights reserved2011

元の言語English
ページ(範囲)499-505
ページ数7
ジャーナルJournal of Biochemistry
149
発行部数5
DOI
出版物ステータスPublished - 2011 5

Fingerprint

Drug Discovery
Medicine
Pharmaceutical Preparations
Pharmacokinetics
Safety
Research

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

これを引用

Drug discovery and development focusing on existing medicines : Drug re-profiling strategy. / Mizushima, Tohru.

:: Journal of Biochemistry, 巻 149, 番号 5, 05.2011, p. 499-505.

研究成果: Article

@article{23d3337f6e644099956f536082fdec8e,
title = "Drug discovery and development focusing on existing medicines: Drug re-profiling strategy",
abstract = "As a new strategy for drug discovery and development, I focus on drug re-profiling as a way to identify new treatments for diseases. In this strategy, the actions of existing medicines, whose safety and pharmacokinetic effects in humans have already been confirmed clinically and approved for use, are examined comprehensively at the molecular level and the results used for the development of new medicines. This strategy is based on the fact that we still do not understand the underlying mechanisms of action of many existing medicines, and as such the cellular responses that give rise to their main effects and side effects are yet to be elucidated. To this extent, identification of the mechanisms underlying the side effects of medicines offers a means for us to develop safer drugs. The results can also be used for developing existing drugs for use as medicines for the treatment of other diseases. Promoting this research strategy could provide breakthroughs in drug discovery and development. The Authors 2011. Published by Oxford University Press on behalf of the Japanese Biochemical Society. All rights reserved2011",
keywords = "comprehensive analysis, drug discovery and development, drug re-profiling, existing medicines",
author = "Tohru Mizushima",
year = "2011",
month = "5",
doi = "10.1093/jb/mvr032",
language = "English",
volume = "149",
pages = "499--505",
journal = "Journal of Biochemistry",
issn = "0021-924X",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Drug discovery and development focusing on existing medicines

T2 - Drug re-profiling strategy

AU - Mizushima, Tohru

PY - 2011/5

Y1 - 2011/5

N2 - As a new strategy for drug discovery and development, I focus on drug re-profiling as a way to identify new treatments for diseases. In this strategy, the actions of existing medicines, whose safety and pharmacokinetic effects in humans have already been confirmed clinically and approved for use, are examined comprehensively at the molecular level and the results used for the development of new medicines. This strategy is based on the fact that we still do not understand the underlying mechanisms of action of many existing medicines, and as such the cellular responses that give rise to their main effects and side effects are yet to be elucidated. To this extent, identification of the mechanisms underlying the side effects of medicines offers a means for us to develop safer drugs. The results can also be used for developing existing drugs for use as medicines for the treatment of other diseases. Promoting this research strategy could provide breakthroughs in drug discovery and development. The Authors 2011. Published by Oxford University Press on behalf of the Japanese Biochemical Society. All rights reserved2011

AB - As a new strategy for drug discovery and development, I focus on drug re-profiling as a way to identify new treatments for diseases. In this strategy, the actions of existing medicines, whose safety and pharmacokinetic effects in humans have already been confirmed clinically and approved for use, are examined comprehensively at the molecular level and the results used for the development of new medicines. This strategy is based on the fact that we still do not understand the underlying mechanisms of action of many existing medicines, and as such the cellular responses that give rise to their main effects and side effects are yet to be elucidated. To this extent, identification of the mechanisms underlying the side effects of medicines offers a means for us to develop safer drugs. The results can also be used for developing existing drugs for use as medicines for the treatment of other diseases. Promoting this research strategy could provide breakthroughs in drug discovery and development. The Authors 2011. Published by Oxford University Press on behalf of the Japanese Biochemical Society. All rights reserved2011

KW - comprehensive analysis

KW - drug discovery and development

KW - drug re-profiling

KW - existing medicines

UR - http://www.scopus.com/inward/record.url?scp=79955407302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955407302&partnerID=8YFLogxK

U2 - 10.1093/jb/mvr032

DO - 10.1093/jb/mvr032

M3 - Article

C2 - 21436140

AN - SCOPUS:79955407302

VL - 149

SP - 499

EP - 505

JO - Journal of Biochemistry

JF - Journal of Biochemistry

SN - 0021-924X

IS - 5

ER -